Selective AR modulators

Modulators of the AR for application in prostate cancer and possibly treating the neurological and muscular degenerative symptoms of androgen defidency form the basis of another field of intense research efforts [79,80]. LGD2226 is a recent example of a tissue-selective AR modulator, which seems to retain some anabolic effects on bone and muscle with reduced proliferative effects on the prostate [81]. 

Although the traditional steroidal agonists and nonsteroidal antagonists are used for a narrow spectrum of diseases (owing to the factors discussed in Section 8.2.1), these molecules have served as archetypical scaffolds (generalized structural templates) for the development of many other related AR chemotypes with potentially broad therapeutic application. Over 64 chemically distinct putative AR agonist templates have been reported, including 22 templates with demonstrated in vivo tissue-selectivity for anabolic tissues [i.e. selective AR modulators (SARMs)]. 

---